^
    Back
    Association details:
    Biomarker:PRKCH overexpression
    Cancer:Chronic Myeloid Leukemia
    Drug:imatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, PDGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    New
    Source:
    Sci Transl Med
    Title:

    A Therapeutically Targetable Mechanism of BCR-ABL-Independent Imatinib Resistance in Chronic Myeloid Leukemia

    Excerpt:
    we derived K562 cell lines that over expressed PRKCH (K562/PRKCH cells) to varying degrees. In several K562/PRKCH cell lines, PKCη levels were comparable to those found in IMSG KD K562 cells (fig. S7A). The elevated PRKCH expression resulted in a 10–20-fold increase in IM resistance (Fig. 3B). 
    DOI:
    https://dx.doi.org/10.1126%2Fscitranslmed.3009073